CMS should monitor the effect on Medicare standalone prescription drug plans of changes in how the drug costs of high-cost ...
Specific changes are needed to lower the barriers to entry for using the hospital and insurer price transparency data, ...
A new Executive Order refocuses federal agency attention on making already-required price data easier to get and use – a ...
The Trump administration’s recent moves to curtail federal funding have transformed the nation’s health infrastructure and sown confusion as to the future of federal support for some of the most ...
Copayment accumulators and maximizers have the potential to harm patients’ access to necessary medicines. Health care payers ...
Health Affairs' Senior Deputy Editor Rob Lott interviews Erica Eliason of Rutgers University on her recent paper that explores how continuous eligibility policies and the Children's Health Insurance ...
Regulatory and reimbursement pathways should consider indirect benefits in addition to direct health benefits when evaluating ...
It is not clear what would become of the federal government’s health care enforcement efforts without the False Claims Act’s qui tam program.
It is fair to wonder why – given its relatively low cost, powerful economic benefits, predominantly state-based control, and demographic neutrality – Republicans are so consistently preoccupied with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback